Monday, January 11, 1999
Photodynamic therapies have generated only moderate interest in the
cancer field, in part because the light-activated therapies can damage other tissues if
they penetrate too far into the body. But PDT is generating excitement in the
ophthalmology community, offering the first viable therapy for age-related macular
QLT PhotoTherapeutics Inc. last week released Phase III data showing
that its Visudyne verteporfin photodynamic therapy preserved vision in a majority of
patients with the "wet" form of AMD, a condition that can cause blindness.